Loading clinical trials...
Loading clinical trials...
Development and Validation of a Circulating Tumor DNA Detection Technique in Patients With Metastatic Choroidal Melanoma
Circulating tumor DNA detection and quantification in patients with metastatic choroidal melanoma.
Technique development: In first step, the different available techniques will be evaluated for specificity and sensibility using serial dilutions of cell lines with or without GNAQ mutation. Validation: The tumor DNA detection rate will be estimated from metastatic uveal patient's blood. The investigators will study 40 patients to obtain at least 15 patients bearing a GNAQ mutation in the primitive tumor or in metastasis. With those 15 patients, the investigators will determinate the most sensitive technique and the best cost/efficiency ratio.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Institut Curie
Paris, France
Start Date
April 1, 2011
Primary Completion Date
February 1, 2012
Completion Date
May 1, 2012
Last Updated
November 24, 2025
40
ACTUAL participants
Blood sampling
BIOLOGICAL
Lead Sponsor
Institut Curie
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions